Now Commercially Available, Both NextSeq 1000 and NextSeq 2000 Sequencers Include Integrated Informatics and Loss-less Compression Technology, Creating an Intuitive User Experience SAN ...

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of ...

Join our webinar where we will highlight key NextSeq™ 1000 and 2000 product updates and features of the on-board DRAGEN Bio-IT platform. We will cover the basics of how the flexibility and streamlined ...

Illumina, Inc. is further extending the reach of the NextSeq 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. The P3 flow cell offers 1.1 billion reads in a ...

The NextSeq 1000 and NextSeq 2000 Systems are thoughtfully designed to enable more insights on your benchtop. With 14 configurations and read lengths from 1 × 50bp to 2 × 300bp, these systems ...

The NextSeq 2000 Systems are designed to support emerging and mid-throughput sequencing applications, accommodating a diverse range of methods such as exome sequencing, target enrichment, single-cell ...

Next-generation sequencing (NGS) is a powerful tool, and it’s use is growing in basic research and clinical laboratories. Illumina continues to raise the bar on genomic sequencing, democratizing NGS ...

As a part of AGBT 2023, Illumina delivered a Spotlight Talk on our NextSeq™ 1000 and 2000 systems product updates and key applications. Within this talk, we take a deep dive into the new 100 and 600 ...

KUALA LUMPUR, Nov 13 -- Illumina Inc is further extending the reach of the NextSeq™ 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. The P3 flow cell offers 1.1 ...

Now Commercially Available, Both NextSeq 1000 and NextSeq 2000 Sequencers Include Integrated Informatics and Loss-less Compression Technology, Creating an Intuitive User Experience Now commercially ...